In a report released yesterday, Christopher Liu from Oppenheimer maintained a Buy rating on KemPharm (NASDAQ: KMPH), with a price target of $13. The company’s shares closed yesterday at $4.60.
Liu observed:
“KMPH reported 2Q18 EPS of $(0.91) vs. our estimate of $(0.86). The story remains relatively the same as we await several near-term catalysts including: (1) oral and intranasal HAP data in 2H18, (2) the announcement of an Apadaz partnership by an NDA submission for in 2019. We updated our model to incorporate 2Q results. Our revised 2018 EPS estimate is $(3.75) vs. $(3.68) prior. The lower EPS forecast is mostly due to higher estimated OpEx derived from our conversation with management.”
According to TipRanks.com, Liu is a 2-star analyst with an average return of 7.5% and a 60.0% success rate. Liu covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Pacira Pharmaceuticals, and Perrigo Company plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for KemPharm with a $12.13 average price target.
See today’s analyst top recommended stocks >>
Based on KemPharm’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $26.22 million. In comparison, last year the company had a GAAP net loss of $6.52 million.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KMPH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.
